Primary Antibodies

The NBS1 antibody is a highly specialized antibody used in Life Sciences research. It is commonly used for the detection and analysis of alpha-fetoprotein (AFP), a biomarker associated with various diseases, including liver cancer. The NBS1 antibody utilizes hybridization techniques to specifically bind to AFP and facilitate its detection.

Goat anti-human IgG/IgA/IgM (H+L) (HRP) was raised in goat using human IgG, IgA and IgM whole molecules as the immunogen.

HIV1 gp120 antibody was raised in rabbit using full length recombinant gp120 (HIV-1) as the immunogen.

The CD22 antibody is a glycoprotein that belongs to the group of polyclonal antibodies. It is commonly used in the field of Life Sciences for research purposes. The CD22 antibody specifically targets CD22, a cell surface protein expressed on B cells. It has been shown to inhibit the growth and proliferation of B cells by binding to CD22 and blocking its function. This antibody has also been found to have anti-inflammatory properties, as it can reduce the levels of pro-inflammatory cytokines such as TGF-beta and TNF-alpha. Additionally, the CD22 antibody has been shown to modulate microvessel density, collagen synthesis, and hyaluronidase activity. Overall, this antibody is a valuable tool for studying B cell biology and exploring potential therapeutic applications in various diseases.

The 6-Fluoro-3-indoxyl-beta-D-galactopyranoside is a powerful antituberculosis drug that falls under the class of rifamycins. It is specifically designed to combat tuberculosis infections by targeting the active compounds responsible for bactericidal activity. This drug inhibits bacterial growth by binding to DNA-dependent RNA polymerase, preventing transcription and replication. Its effectiveness has been proven through extensive research using advanced techniques like the patch-clamp technique on human erythrocytes. The metabolization process involves various transformations such as hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. Additionally, it exhibits high affinity towards markers expressed in Mycobacterium tuberculosis strains, effectively inhibiting their growth in culture.

Rituximab is a glycosylated monoclonal antibody that binds to the CD20 cell surface protein which is widely expressed on B-cells. Through the binding of rituximab’s Fc portion, the antibody-dependent cellular cytotoxicity pathway (ADCC) and the complement-dependent cytotoxicity (CDC) pathway are initiated, both leading to B-cell lysis (Chisari, 2021). In addition, direct apoptosis can be the result of the inhibition of various B-cell signalling pathways. Rituximab is used in targeted therapy for chronic lymphocytic leukaemia (CLL), non-Hodgkin lymphoma (NHL) and some non-cancer pathologies, such as, multiple sclerosis (Johnson, 2001).

Please enquire for more information about Campylobacter Jejuni Antigen including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about Recombinant EBV Capsid Antigen, p18 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about Cytomegalovirus (CMV) EIA Antigen including the price, delivery time and more detailed product information at the technical inquiry form on this page